Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
Immunomodulators have been used in recent years to reactivate host anti-tumor immunity in several hematological malignancies. This report describes the effect of activating natural killer T (NKT) cells by α-Galactosylceramide (α-GalCer) in the 5T33MM model of multiple myeloma (MM). NKT cells are T l...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/29eb632b6752483d91a0d788feb4a78a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:29eb632b6752483d91a0d788feb4a78a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:29eb632b6752483d91a0d788feb4a78a2021-11-18T07:43:27ZPreclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.1932-620310.1371/journal.pone.0065075https://doaj.org/article/29eb632b6752483d91a0d788feb4a78a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23741460/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Immunomodulators have been used in recent years to reactivate host anti-tumor immunity in several hematological malignancies. This report describes the effect of activating natural killer T (NKT) cells by α-Galactosylceramide (α-GalCer) in the 5T33MM model of multiple myeloma (MM). NKT cells are T lymphocytes, co-expressing T and NK receptors, while invariant NKT cells (iNKTs) also express a unique semi-invariant TCR α-chain. We followed iNKT numbers during the development of the disease in both 5T33MM mice and MM patients and found that their numbers dropped dramatically at the end stage of the disease, leading to a loss of total IFN-γ secretion. We furthermore observed that α-GalCer treatment significantly increased the survival of 5T33MM diseased mice. Taken together, our data demonstrate for the first time the possibility of using a preclinical murine MM model to study the effects of α-GalCer and show promising results of α-GalCer treatment in a low tumor burden setting.Haneen NurKarel FostierSandrine AspeslaghWim RenmansElisabeth BertrandXavier LeleuMérédis FavreauKarine BreckpotRik SchotsMarc De WaeleEls Van ValckenborghElke De BruyneThierry FaconDirk ElewautKarin VanderkerkenEline MenuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e65075 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Haneen Nur Karel Fostier Sandrine Aspeslagh Wim Renmans Elisabeth Bertrand Xavier Leleu Mérédis Favreau Karine Breckpot Rik Schots Marc De Waele Els Van Valckenborgh Elke De Bruyne Thierry Facon Dirk Elewaut Karin Vanderkerken Eline Menu Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| description |
Immunomodulators have been used in recent years to reactivate host anti-tumor immunity in several hematological malignancies. This report describes the effect of activating natural killer T (NKT) cells by α-Galactosylceramide (α-GalCer) in the 5T33MM model of multiple myeloma (MM). NKT cells are T lymphocytes, co-expressing T and NK receptors, while invariant NKT cells (iNKTs) also express a unique semi-invariant TCR α-chain. We followed iNKT numbers during the development of the disease in both 5T33MM mice and MM patients and found that their numbers dropped dramatically at the end stage of the disease, leading to a loss of total IFN-γ secretion. We furthermore observed that α-GalCer treatment significantly increased the survival of 5T33MM diseased mice. Taken together, our data demonstrate for the first time the possibility of using a preclinical murine MM model to study the effects of α-GalCer and show promising results of α-GalCer treatment in a low tumor burden setting. |
| format |
article |
| author |
Haneen Nur Karel Fostier Sandrine Aspeslagh Wim Renmans Elisabeth Bertrand Xavier Leleu Mérédis Favreau Karine Breckpot Rik Schots Marc De Waele Els Van Valckenborgh Elke De Bruyne Thierry Facon Dirk Elewaut Karin Vanderkerken Eline Menu |
| author_facet |
Haneen Nur Karel Fostier Sandrine Aspeslagh Wim Renmans Elisabeth Bertrand Xavier Leleu Mérédis Favreau Karine Breckpot Rik Schots Marc De Waele Els Van Valckenborgh Elke De Bruyne Thierry Facon Dirk Elewaut Karin Vanderkerken Eline Menu |
| author_sort |
Haneen Nur |
| title |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| title_short |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| title_full |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| title_fullStr |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| title_full_unstemmed |
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. |
| title_sort |
preclinical evaluation of invariant natural killer t cells in the 5t33 multiple myeloma model. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/29eb632b6752483d91a0d788feb4a78a |
| work_keys_str_mv |
AT haneennur preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT karelfostier preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT sandrineaspeslagh preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT wimrenmans preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT elisabethbertrand preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT xavierleleu preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT meredisfavreau preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT karinebreckpot preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT rikschots preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT marcdewaele preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT elsvanvalckenborgh preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT elkedebruyne preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT thierryfacon preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT dirkelewaut preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT karinvanderkerken preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel AT elinemenu preclinicalevaluationofinvariantnaturalkillertcellsinthe5t33multiplemyelomamodel |
| _version_ |
1718423024833658880 |